Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24448861 | 0.90 | FAAH (0.41) | MEN1KMT2ALMNAEPHX2FAAH | |
| SCHEMBL13154398 | 0.83 | KAT8 (0.40) | MEN1KMT2ALMNAEPHX2FAAH | |
| SCHEMBL24448805 | 0.83 | FAAH (0.32) | EPHX2FAAH | |
| SCHEMBL4404400 | 0.81 | ALDH1A1 (0.43) | TSHRCYP3A4CYP2C19CYP19A1ALDH1A1 | |
| SCHEMBL4402799 | 0.81 | TSHR (0.39) | KMT2ATSHRCYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL4409415 | 0.80 | CYP3A4 (0.35) | EPHX2KAT8CYP3A4CYP2C19CYP19A1 | |
| SCHEMBL12945381 | 0.80 | CYP3A4 (0.35) | TSHRCYP3A4CYP2C19CYP19A1ALDH1A1 | |
| SCHEMBL25957283 | 0.79 | MEN1 (0.38) | MEN1KMT2ALMNAEPHX2FAAH | |
| SCHEMBL24449559 | 0.79 | CYP3A4 (0.35) | KAT8CYP3A4CYP2C19CYP19A1ALDH1A1 | |
| SCHEMBL22825211 | 0.78 | MEN1 (0.37) | MEN1KMT2ALMNAEPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | MEN1 1860/4885KMT2A 33/4885LMNA 2503/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | MEN1 1860/4885KMT2A 33/4885LMNA 2503/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | MEN1 1860/4885KMT2A 33/4885LMNA 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.